Full text
PDF![775](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1b/1844514/cbae6ce1bd2e/brmedj02543-0045.png)
![776](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1b/1844514/b2b0593e2b3e/brmedj02543-0046.png)
![777](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1b/1844514/886027be287c/brmedj02543-0047.png)
![778](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1b/1844514/1e141849a886/brmedj02543-0048.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- JANCIK E., ZELENKA M., TOUSEK J., MAKOVA M. CHEMOTHERAPY FOR PATIENTS WITH CULTURES RESISTANT TO STREPTOMYCIN, ISONIAZID AND PAS. Tubercle. 1963 Dec;44:443–445. [PubMed] [Google Scholar]
- SOMNER A. R., BRACE A. A. Ethionamide, pyrazinamide and cycloserine used successfully in the treatment of chronic pulmonary tuberculosis. Tubercle. 1962 Dec;43:345–360. doi: 10.1016/s0041-3879(62)80003-8. [DOI] [PubMed] [Google Scholar]
- ZIERSKI M. TREATMENT OF PATIENTS WITH CULTURES RESISTANT TO THE PRIMARY ANTI-TUBERCULOSIS DRUGS. Tubercle. 1964 Jun;45:96–100. doi: 10.1016/s0041-3879(64)80065-9. [DOI] [PubMed] [Google Scholar]